DRP1-mediated mitochondrial fission is essential to maintain cristae morphology and bioenergetics

Gabriella L. Robertson[1], Stellan Riffle[1], Mira Patel[1], Andrea Marshall[2], Heather Beasley[2], Edgar Garza Lopez[2], Jianqiang Shao[3], Zer Vue[2], Maria S. Stoll[4], Sholto de Wet[5], Rensu P. Theart[6], Ben Loos[6], Antentor Hinton Jr.[2], Jason A. Mears[4], and Vivian Gama[1,7,8,9]

[1]Vanderbilt University, Cell and Developmental Biology, Nashville, TN.
[2]Vanderbilt University, Molecular Physiology and Biophysics, Nashville, TN.
[3]Central Microscopy Research Facility, University of Iowa, Iowa City, IA.
[4]Case Western Reserve University, Department of Pharmacology and Center for Mitochondrial Diseases, Cleveland, OH.
[5]Stellenbosch University, Department of Physiological Sciences, Stellenbosch, South Africa
[6]Stellenbosch University, Department of Electrical and Electronic Engineering, Stellenbosch, South Africa
[7]Vanderbilt University, Vanderbilt Center for Stem Cell Biology, Nashville, TN
[8]Vanderbilt University, Vanderbilt Brain Institute, Nashville, TN

[9]Corresponding author

Correspondence should be addressed to:

Vivian Gama
PMB407935
465 21st Avenue South, 4150A
Vanderbilt University
Nashville, TN 37240-7935
Tel: (615) 875-9490
vivian.gama@vanderbilt.edu

Running title: DRP1 mutations associated with EMPF1

Keywords: fibroblasts, DRP1, mitochondria, peroxisomes, cristae, glycolysis, oxidative phosphorylation

Abstract

Mitochondria and peroxisomes are both dynamic signaling organelles that constantly undergo

fission. While mitochondrial fission is known to coordinate cellular metabolism, proliferation, and

apoptosis, the physiological relevance of peroxisome dynamics and the implications for cell fate

are not fully understood. DRP1 (dynamin-related protein 1) is an essential GTPase that executes

both mitochondrial and peroxisomal fission. Patients with *de novo* heterozygous missense

mutations in the gene that encodes DRP1, *DNM1L (Dynamin 1 Like)*, present with

encephalopathy due to defective mitochondrial and peroxisomal fission (EMPF1). EMPF1 is a

devastating neurodevelopmental disease with no effective treatment. To interrogate the

mechanisms by which DRP1 mutations cause cellular dysfunction, we used human-derived

fibroblasts from patients with mutations in DRP1 who present with EMPF1. As expected, patient

cells display elongated mitochondrial morphology and lack of fission. Patient cells display a lower

coupling efficiency of the electron transport chain, increased proton leak, and upregulation of

glycolysis. In addition to these metabolic abnormalities, mitochondrial hyperfusion results in

aberrant cristae structure and hyperpolarized mitochondrial membrane potential, both of which

are tightly linked to the changes in metabolism. Peroxisome structure is also severely elongated

in patient cells and results in a potential functional compensation of fatty acid oxidation.

Understanding the mechanism by which DRP1 mutations cause these metabolic changes will

give insight into the role of mitochondrial dynamics in cristae maintenance and the metabolic

capacity of the cell, as well as the disease mechanism underlying EMPF1.

Introduction

Mitochondrial dynamics are controlled and executed by a vast group of proteins and other

organelles. The underlying morphology of the mitochondria is an important determinant for the

ability of this organelle to regulate a variety of cellular processes, such as apoptosis, cell fate, lipid

biosynthesis, and epigenetic modifications (Bayraktar et al., 2019; Iwata et al., 2020; Khacho et

al., 2016; King et al., 2021; Prigione and Adjaye, 2011; Rasmussen et al., 2020; Vantaggiato et

al., 2019). Mitochondrial fusion is primarily catalyzed by the large GTPases Mitofusin 1 and

Mitofusin 2 at the outer mitochondrial membrane (Chen et al., 2003). The GTPase OPA1 (Optic

Atrophy 1) is responsible for executing fusion of the inner mitochondrial membrane (Alexander et

al., 2000; Delettre et al., 2000). Mitochondrial fission, mediated through the large GTPase DRP1

(Dynamin-related protein 1), is orchestrated by a complex sequence of events (Fonseca et al.,

2019; Smirnova et al., 2001). The first steps of mitochondrial fission include contact with the

endoplasmic reticulum (ER) and replication of the mitochondrial genome (Friedman et al., 2011;

Lewis et al., 2016). This is followed by contact and pre-constriction by actin filaments, which are

associated with the ER membrane (Chakrabarti et al., 2018; Hatch et al., 2016, 2014; Ji et al.,

2017, 2015; Li et al., 2015). Fission is also regulated through adaptor proteins at the outer

mitochondrial membrane, including MiD49 (Mitochondrial Dynamics Protein 49), MiD51

(Mitochondrial Dynamics Protein 51), MFF (Mitochondrial Fission Factor), and FIS1 (Fission,

Mitochondrial 1), however, their distinct roles in fission are not completely understood (Losón et

al., 2013; Osellame et al., 2016; Palmer et al., 2013). After the association with adaptor proteins,

DRP1 then forms a multimeric ring around the mitochondria and hydrolyzes GTP to GDP causing

a confirmational change in the ring that executes fission (Chang and Blackstone, 2007; Fröhlich

et al., 2013; Nagashima et al., 2020). DRP1 is essential for mitochondrial fission and without

functional DRP1, the mitochondrial network becomes hyperfused. In addition to the effects on

mitochondrial morphology, DRP1 also mediates the fission of peroxisomes (Koch et al., 2003).

Peroxisomes are highly specialized organelles vital for the beta oxidation of very-long-chain fatty

acids, detoxification of reactive oxygen species (ROS), production of cholesterol, bile acids, and

plasmalogens, which contribute to the phospholipid content in the brain white matter (Chandel,

2021; Ding et al., 2021; Ferreira et al., 2021; Lodhi and Semenkovich, 2014; Ravi et al., 2021;

Schrader et al., 2020; Sugiura et al., 2017). The adaptor proteins MFF and FIS1 are also involved

in DRP1 recruitment to sites of peroxisome fission (Gandre-Babbe and Van Der Bliek, 2008;

Itoyama et al., 2013; Koch and Brocard, 2012). The contacts between mitochondria and

peroxisomes are essential for linking peroxisomal β-oxidation and mitochondrial ATP generation

by the electron transport chain (ETC), maintenance of redox homeostasis, and lipid transfer

(Chandel, 2021; Fan et al., 2016; Fransen et al., 2017). Thus, peroxisomal and mitochondrial

metabolic activities are functionally interconnected. Consistent with this, peroxisomal disorders

caused by mutations in genes involved in the biogenesis and function of peroxisomes, are often

associated with mitochondrial dysfunction (Tanaka et al., 2019). This communication may be

particularly important during brain development and metabolic stress. However, the molecular

mechanisms that facilitate this communication are still poorly understood.

In mouse models, global DRP1 knockout is embryonic lethal (Ishihara et al., 2009; Wakabayashi

et al., 2009). With the advent of exome sequencing, patients with *de novo* mutations in the gene

that encodes DRP1, *DNM1L (Dynamin 1 Like)*, have been identified (Chao et al., 2016; Fahrner

et al., 2016; Keller et al., 2021; Liu et al., 2021; Longo et al., 2020; Nasca et al., 2016; Nolan et

al., 2019; Ryan et al., 2018; Sheffer et al., 2016; Vandeleur et al., 2019; Waterham et al., 2007;

Yoon et al., 2016). The disease associated with mutations in *DNM1L* is known as encephalopathy

due to defective mitochondrial and peroxisomal fission-1 (EMPF1) (OMIM 614388). Most reported

mutations are heterozygous missense mutations. Patients present with heterogeneous symptoms

including neurodevelopmental delay, seizures, muscle abnormalities, and ataxia. Patient

fibroblasts show very elongated mitochondrial networks and elevated lactate levels, suggesting

an impairment in oxidative phosphorylation (Liu et al., 2021; Whitley et al., 2018). Currently, there

is no effective treatment or cure for patients effected by DRP1 mutations. The life expectancy for

most patients with DRP1 mutations is childhood to early adolescence (Ryan et al., 2018).

Although other proteins and organelles are involved in fission, DRP1 has been shown to be

indispensable for mitochondrial fission (Csordás et al., 2006; Fonseca et al., 2019; Kamerkar et

al., 2018; Li et al., 2015; Nagashima et al., 2020; Smirnova et al., 2001), yet the cellular

consequences of DRP1 dysfunction are not well understood. In this study, we aimed to

characterize the effects of two DRP1 mutations identified in patients with EMPF1, the G32A

mutation, which lies in the catalytic GTPase domain of DRP1, and the R403C mutation, which

lies in the stalk domain (Fröhlich et al., 2013) (Figure 1A), on mitochondrial network morphology,

cristae ultrastructure, and related metabolic adaptations, to gain fundamental insight into the

cellular adaptations to dysfunctional organelle fission and the pathophysiology of EMPF1.

Here, we resolve and quantify mitochondrial and peroxisomal morphological features associated

with EMPF1-associated mutations and reveal their impact on cellular metabolism, to put into

perspective the clinical findings that were previously described (Fahrner et al., 2016; Liu et al.,

2021; Ryan et al., 2018). We found that the inability of DRP1 to fragment the mitochondria in

patient-derived fibroblasts leads not only to the hyperfusion phenotype previously described, but

also to delayed cell death in response to apoptotic signals, aberrant mitochondrial cristae

structure, and hyperpolarized mitochondrial membrane potential. Metabolically, the changes in

mitochondrial and peroxisomal morphology result in inefficiency of ETC coupling oxygen

consumption with ATP production and upregulation of glycolysis. Altogether, these data indicate

that mitochondrial and peroxisomal fission influence dynamics of the inner mitochondrial

membrane and the metabolic state of the cell.

Results

DRP1 variants found in patients have dominant negative effects that alter the expression

of critical proteins at the mitochondria

Light microscopy studies have shown the profound alterations of mitochondrial fission in cells

from patients harboring mutations in DRP1 (Ryan et al., 2018; Whitley et al., 2018). These studies

highlighted the clinical relevance of mitochondrial fission in neural development. We quantified

the morphology of the mitochondria in patient-derived primary fibroblasts at super resolution level

using structured illumination microscopy (SIM). Both patient fibroblast lines showed increased

mitochondrial volume, surface area and major axis length, consistent with a hyperfused

mitochondrial morphology, as reported for DRP1 null cells (Fonseca et al., 2019; Kamerkar et al.,

2018; Smirnova et al., 2001) (Fig. 1B-C). Live-cell imaging of mitochondria stained with

MitoTracker confirmed that mitochondrial fission events are rare in patient cells compared to

control fibroblasts (Supplementary Fig. 1A). High resolution three-dimensional images of control

and patient fibroblasts were obtained using serial block facing-scanning electron microscopy

(SBF-SEM) (Garza-Lopez et al., 2021). Manual segmentation and stack reconstruction of the

mitochondrial networks validated the increased length and volume of the mitochondrial networks

as well as increased mitochondrial complexity index (MCI) in patient fibroblasts (Fig. 1D-E). MCI

is a quantitative measurement of network complexity, which takes into account both volume and

surface area of the mitochondria (MCI = $SA^3 / 16\pi^2 V^2$) (Faitg et al., 2021; Vincent et al., 2019).

Both mutations in DRP1 result in significant alterations of the mitochondrial network with G32A

fibroblasts showing slightly more severe elongation than R403C (Fig. 1E and Supplementary Fig.

1B).

Both mutations in DRP1 are found to be heterozygous in patients, suggesting that mutant DRP1

has a dominant effect that can interfere with the ability of wild-type DRP1 to fragment the

mitochondria. To test this, we generated mCherry tagged- constructs containing the patient

derived mutations and expressed them in human fibroblasts homozygous for endogenous wild-

type DRP1. Overexpression of mCherry-DRP1-G32A and mCherry-DRP1-R403C by transient

transfection in wild-type fibroblasts demonstrated that, as previously described (Montecinos-

Franjola et al., 2020, Fahrner et al., 2016; Ryan et al., 2018; Whitley et al., 2018), the

mitochondrial hyperfusion seen in patient cells is not due to the genetic background and that these

mutations act in a dominant negative manner (Fig. 1F-G). While both mutations of DRP1

significantly impaired DRP1 function in human fibroblasts, the G32A show a slightly more severe

phenotype than R403C.

Hyperfusion of the mitochondrial membrane due to sequestration and inactivation of DRP1 is

thought to lead to unopposed fusion events that increase the severity of mitochondrial elongation

(Palmer et al., 2013). We examined the effects of DRP1 mutations on the protein expression

levels of mitochondrial dynamics proteins. Both Mitofusin 1 and Mitofusin 2 were expressed at

lower levels in patient cells than in control cells. However, there was no significant difference in

the expression of OPA1 (Fig. 2A). These data show that there is a reduction in the expression of

mitochondrial outer membrane fusion proteins in patient cells, suggesting that active

mitochondrial fission promotes protein stability at the outer mitochondrial membrane and

compensatory fusion events.

Phosphorylation of DRP1 at Serine 616 has been proposed to be a critical determinant of DRP1

recruitment and activity (Koch and Brocard, 2012; Taguchi et al., 2007; Valera-Alberni et al.,

2021). Whether mutations in DRP1 found in patients with EMPF1 affect the levels of

phosphorylation at Serine 616 has not been explored. We examined DRP1 levels in patient

derived fibroblasts. Although there was no significant difference in total DRP1 expression, G32A

patient cells expressed significantly less pS616-DRP1 than control cells (Fig. 2B). Since G32A

mutation impairs DRP1 phosphorylation to a greater extent than the R403C mutation, the GTPase

domain of DRP1 may be structurally or functionally involved in DRP1 phosphorylation. We

wondered whether the expression of one copy of mutant DRP1 in patient fibroblasts affected the

recruitment of endogenous pS616-DRP1 to the mitochondria. To test this, we quantified the

recruitment of phosphorylated DRP1 to the outer mitochondrial membrane using super-resolution

microscopy. On average, there was no significant difference in the recruitment of pS616-DRP1 to

the mitochondria in patient cells and control cells (Fig. 2C-D). While in all cell lines, pS616-DRP1

was found in close contact to the mitochondrial membrane, in the patient fibroblasts this

interaction appeared less transient. These results point to generalized stalling of the fission events

in patient fibroblasts.

The onset of apoptosis is accompanied by mitochondrial remodeling, stable association of DRP1

to the mitochondrial membrane, and increased fragmentation of the mitochondrial membrane

(Martinou and Youle, 2006; Wasiak et al., 2007). In DRP1 deficient cells, this remodeling of

mitochondria is significantly reduced and the onset of cell death is delayed (Lee et al., 2004). To

determine the effects of mitochondrial stress on mitochondrial fragmentation in patient fibroblasts,

we quantified changes in mitochondrial fission in response to CCCP treatment. As previously

shown using RNAi experiments in HeLa cells, patient fibroblasts showed reduced mitochondrial

fragmentation induced by CCCP compared to control cells (Fig. 2E-F). Although some

mitochondrial fragmentation may occur, mitochondrial volume and major axis length are

significantly larger in patient cells treated with CCCP than control cells. Upon apoptosis, BAX

translocates to the mitochondria and cytochrome *c* is released to the cytosol (Smaili et al., 2001).

While in DRP1 depleted cells BAX is recruited to the mitochondria, cytochrome *c* release is

delayed. Consistent with this, patient fibroblasts show higher cell survival when treated with CCCP

and Etoposide; as well as, lower caspase-3 activity than control fibroblasts when treated with STS

(Supplementary Fig. 2A-B). Interestingly, basal levels of both BAX and BAK are significantly

reduced in patient fibroblasts with mutations in DRP1 (Supplementary Fig. 2C). Levels of the anti-

apoptotic protein MCL-1 were significantly reduced in G32A fibroblasts but not in R403C

fibroblasts, while BCL-XL expression levels remained relatively constant in all cell lines. Thus,

patient fibroblasts may display a compensatory adaptation to reduce the basal levels of BAX/BAK

activation. Whether this reduction in the ability to undergo apoptosis in response to mitochondrial

stress is a widespread phenomenon in all tissues of EMPF1 patients and/or whether apoptosis

inhibition results in deleterious accumulation of mitochondrial and nuclear DNA encoded

mutations remains unexplored. No significant alteration in the protein expression of DRP1

adaptors was detected (Supplementary Fig. 2D).

Mitochondrial hyperfusion in DRP1 mutant fibroblasts leads to higher glycolytic rate and

increased mitochondrial membrane potential

Mitochondrial morphology is tightly linked to metabolic function (Dorn, 2015; Wai and Langer,

2016); thus, we assessed the effects of DRP1 patient mutations on cellular metabolism by

measuring rates of glycolysis and oxidative phosphorylation (OXPHOS) in cells using the

sensitive high-throughput Seahorse XF Analyzer. The Seahorse analyzer measures extracellular

oxygen consumption as a readout of OXPHOS and extracellular acidification as a readout of

glycolysis. Basal and maximal oxygen consumption was not significantly different in mutant cells

compared to control, suggesting no major defects in ATP production (Fig. 3A). However, proton

leak was significantly higher in the G32A patient cells and coupling efficiency was significantly

lower in both patient lines (Fig. 3B). Therefore, although basal ATP production is not perturbed in

the mutant cells, the ETC is not effectively coupling substrate oxidation and ATP synthesis.

Extracellular acidification rate was significantly increased in both patient lines, consistent with an

upregulation of glycolysis (Fig. 3A) and the hyperlactacidemia observed in more than 50% of

patients with mutations in DRP1 (Liu et al., 2021). A glycolytic rate assay confirmed that both

basal and compensatory glycolysis are higher in both patient lines (Fig. 3C). Thus, although the

cells are capable of producing ATP, DRP1 mutations cause a defect in OXPHOS efficiency and

a slight metabolic dependency on glycolysis (Fig. 3C and Supplementary Fig. 3A).

To dissect functional differences in the ETC complexes at the mitochondria between control and

mutant fibroblasts, we complemented our studies with the high-resolution Oxygraph-2k (O2k,

Oroboros Instruments, Austria) which measures OXPHOS within intact, permeabilized cells (Ye

and Hoppel, 2013). This method includes two protocols run in parallel (Hsiao and Hoppel, 2018;

Krahenbuhl et al., 1991; Ye and Hoppel, 2013) using a number of selective substrates and

inhibitors to measure the rates of oxygen consumption attributed to distinct ETC complexes. In

protocol 1, the activity of complexes I, II, and IV is sequentially assessed and measured. First,

intact cellular respiration (ICR) is determined to obtain a baseline rate prior to the addition of any

substrates. Consistent with the Seahorse analyzer, the DRP1 mutant fibroblasts showed

equivalent baseline OXPHOS to control fibroblasts (Fig. 3D). Then, substrates for Complex I (CI),

malate (M) and pyruvate (P), were added, but elicit no impact on the cellular respiration as these

substrates remain extracellular (Fig. 3E). To permeabilize the cell membrane, digitonin (Dig) was

added, resulting in diluted intracellular content and allowing M + P to enter the cell for oxidation,

which reveals the leak rate in the absence of ADP. In this assay, there was not a significant

increase in proton leak between control and mutant fibroblasts when substrate was not limited

(Fig. 3F). Based on our results from Seahorse where the major phenotype between the mutant

lines and the control fibroblasts was in the decreased coupling efficiency of the mitochondria, we

examined the functionality of each of the ETC complexes. Thus, adenosine diphosphate (ADP)

was added, to stimulate respiration of coupled mitochondria (also known as state 3)(Hsiao and

Hoppel, 2018; Ye and Hoppel, 2013), followed by addition of glutamate (G), another CI substrate,

and succinate (S), a complex II substrate. The addition of these compounds provides an

assessment of the coupled CI OXPHOS and the coupled CI + CII OXPHOS. While we found no

significant differences in the CI capacity (Fig. 3G), the DRP1 G32A fibroblasts showed a

significant decrease in the coupled CI/CII OXPHOS (Fig. 3H). We then assess the maximal

oxidative capacity, by adding the uncoupler, trifluoromethoxy carbonylcyanide phenylhydrazone

(FCCP), and saw a slight decrease, albeit not significant in the DRP1 G32A fibroblasts (Fig. 3I).

Next, the addition of rotenone (Rot), an inhibitor of CI, assesses the uncoupled CI and CII rates

individually. No significant differences were detected (Fig. 3J-K). To assess complex CIV Oxphos,

we added tetramethyl-p-phenylenediamine (TMPD) and ascorbate (AS), which donates electrons

to cytochrome c (cyt c), then a CIV inhibitor, azide, was added. No differences in CIV activity were

detected (Fig. 3L). Thus, our assessment of complexes I, II, and IV in the mutant G32A fibroblasts

revealed a potential deficiency in the linked CI/CII mitochondrial OXPHOS. This decrease in

linked CI/CII activity is likely due to the additive effect of combined rate since both CI and CII

trended down on their own. This decreased in CI and CII activity was not seen in the R403C

fibroblasts.

In protocol 2, we measured the OXPHOS for FAO and complex III (CIII). The ICR rate was first

assessed (Fig 3M). Followed by the addition of Malate (M) and palmitoylcarnitine (Pal), a long-

chain fatty acid derivative (Fig. 3N-O). We found that the ICR was significantly higher in the DRP1

R403C mutant fibroblasts (Fig. 3M-N) and significantly decreased in DRP1 G32A fibroblasts upon

addition of M and P (Fig. 3O). Upon permeabilization with Digitonin, ADP was then added to

assess the state 3 rate of Pal oxidation. No significant overall differences in the rate of FAO were

detected under these conditions (Fig. 3P). We followed by the addition of Rot to diminish any

non-mitochondrial oxidation, and duroquinol (DHQ), a CIII substrate, to assess the coupled CIII

rate (Fig. 3Q). Finally, the uncoupled CIII rate was evaluated via the addition of FCCP. There

were no differences in the coupled CIII activity or the uncoupled CIII oxidation. Collectively, our

results showed impaired coupled CI/CII activity in G32A but not R403C fibroblasts, and a potential

increase in FAO capacity in R403C mutants.

The upregulation of glycolysis with no accompanied increase in OXPHOS led us to interrogate a

potential impairment in pyruvate transport. Two proteins are essential for mitochondrial pyruvate

transport in humans, Mitochondrial Pyruvate Carrier 1 and 2 (MPC1 and MPC2) (Bricker et al.,

2012; Herzig et al., 2012). MPC1 and MPC2 associate to form an ~150-kilodalton complex in the

inner mitochondrial membrane. Real time quantitative PCR (RT-qPCR) gene expression analysis

showed a significant downregulation of *MPC2* expression in R403C cells and *MPC1* in both

patient lines (Supplementary Fig. 3B). These data suggest that the upregulation in glycolysis seen

in DRP1 mutant patient fibroblasts is accompanied by impaired pyruvate import into the

mitochondria. We examined the expression of MPC1 and MPC2, using Western blot, which

revealed a significant decrease in MPC2 expression in the R403C cells (Supplementary Fig. 3C)

The major contributor of the proton motive force of the ETC is the mitochondrial membrane

potential, which drives OXPHOS. Thus, changes in coupling efficiency can point to perturbation

of the mitochondrial membrane potential and the maintenance of key ion gradients. We

investigated this possibility using the fluorescent sensor Tetramethylrhodamine, ethyl ester

(TMRE). TMRE is a cell-permeant, cationic, red-orange fluorescent dye that is sequestered by

polarized mitochondria. We found that mitochondrial membrane potential as reported by TMRE

was significantly increased in patient fibroblasts (Fig. 4), indicative of hyperpolarization of the

mitochondria.

DRP1 mutations alter mitochondrial cristae morphology

Cristae topology readjustments participate in energy balance control (Eramo et al., 2020; Kondadi

et al., 2020). The hyperpolarization of the mitochondrial membrane detected in patient fibroblasts

lead us to assess the effects of DRP1 mutations on cristae morphology. We used a previously

optimized method to quantify and analyze cristae morphology changes from transmission electron

microscopy (TEM) (Eisner et al., 2017; Lam et al., 2021). In this method, cristae abundance is

calculated by manually quantifying the number of cristae per mitochondrion, and a score between

0 (worst) and 4 (best) is assigned based on the morphology: (0—no well-defined cristae, 1—no

cristae in more than ~75% of the mitochondrial area, 2—no cristae in approximately ~25% of

mitochondrial area, 3—many cristae (over 75% of area) but irregular, 4—many regular cristae)

(Supplementary Fig. 4A). TEM of patient fibroblasts confirmed the mitochondrial elongation

observed in SIM (Supplementary Fig. 4B-E) and revealed differences in the cristae structure (Fig.

5A). The quantification of cristae morphology demonstrated a reduced cristae score and

decreased cristae number relative to mitochondrial length in DRP1-deficient cells compared with

the control cells (Fig. 5B). These data link aberrant outer mitochondrial membrane fission caused

by DRP1 mutations to generalized cristae structural changes. The structure and respiratory

function of mitochondrial cristae are maintained by the mitochondrial contact sites and cristae

organizing system (MICOS) – a large complex of scaffolding and membrane shaping proteins

localized at the inner mitochondrial membrane. Given the reduced cristae score, we examined

expression of some key components of the MICOS complex. *MIC19, MIC25,* and *MIC60* are all

reduced in either one or both patient lines at the mRNA level; however, protein expression is not

significantly changed (Supplementary Fig. 4F). Thus, the structural abnormalities seen in patient

fibroblasts are not due to changes in the expression of MICOS proteins. Additional biochemical

assays are needed to assess the functionality of these proteins in the context of EMPF1.

Patient fibroblasts display hyperfused peroxisomes

In addition to catalyzing mitochondrial fission, DRP1 also participates in peroxisomal fission

(Kamerkar et al., 2018). While fission of peroxisomes has been demonstrated to be involved in

de novo peroxisomal biogenesis, the functional consequences of peroxisomal fission are not

completely understood. Previous reports using EMPF1 patient fibroblasts have not reported

elongation of peroxisomes, but DRP1 null cells have been reported to have hyperfused

peroxisomes (Kamerkar et al., 2018). To interrogate the effects of DRP1 mutations on peroxisome

morphology, we performed super-resolution microscopy. SIM revealed that both mutations in

DRP1 result in significant elongation of peroxisomes (Fig. 6A). Quantification of the peroxisome

structure shows an increase in volume, surface area, and length of peroxisomes (Fig. 6B),

demonstrating that DRP1 mutations found in patients with EMPF1 result in impaired peroxisome

fission.

Since peroxisomes and mitochondria are hubs for the regulation of fatty acid metabolism, we first

tested whether the dramatic changes in morphology would alter the expression of key genes

involved in fatty acid oxidation in patient fibroblasts. The expression of these genes have

previously been reported to increase in a DRP1 phosphomimetic mouse model (Valera-Alberni et

al., 2021). RT-qPCR analysis showed that the expression of carnitine palmitoyltransferase I,

CPT1, and acyl-coA dehydrogenase medium chain, *ACADM*, are significantly lower in patient

cells compared to control (Fig. 6C). CPT1 is associated with the outer mitochondrial membrane

and is responsible for catalyzing the transfer of the acyl group of acyl-CoA to L-carnitine. Fatty

acids are then able to move from the cytosol into the inner membrane space of the mitochondria

and the matrix, where fatty acid oxidation occurs. *ACADM* encodes for the medium-chain-acyl-

CoA dehydrogenase (MCAD) protein, which catalyzes the first step of mitochondrial fatty acid

beta-oxidation. Thus, the reduction in *CPT1* and *ACADM* expression may hinder the ability of the

mitochondria to carryout fatty acid oxidation.

To examine the ability of patient fibroblasts to perform fatty acid oxidation, we used the Seahorse

analyzer to quantify oxygen consumption rates of patient fibroblasts treated with either vehicle or

etomoxir, a CPT1 inhibitor. The cells were cultured with minimal glucose and glutamine and high

L-carnitine and palmitate to promote fatty acid oxidation over glycolysis or glutaminolysis. Control

fibroblasts treated with etomoxir, an inhibitor of CPT1, show a reduction in maximal respiration

following FCCP injection. In contrast, the G32A patient-derived cells show no change in OCR with

etomoxir treatment and the R403C patient-derived cells show an increase in maximal respiration

following FCCP injection (Fig. 6D-E). These data indicate that in contrast to the reliance of control

cells to long chain fatty acid oxidation under conditions of maximal respiration, both patient lines

have lost this dependency and adapted to the inhibition of long-chain fatty acid import into

mitochondria under these conditions. These data show that fibroblasts with DRP1 mutations

appear to have compensatory adaptations to alterations in long-chain fatty acid oxidation.

Mitochondrial hyperfusion is rescued by MFN2 silencing

The exact mechanisms by which the mitochondrial fusion machinery is positioned to sites of

fusion are not completely understood. However, fission and fusion events occur in rapid

succession (Liu et al., 2009) and fission and fusion machineries localize in close proximity at the

endoplasmic reticulum membrane contact sites (Abrisch et al., 2020). Given the intricate

relationship between these opposing dynamics, we examined the rates of fission and fusion in

live cells to determine if defects in fission may impact fusion rates. Our analysis in live cells

showed that in control cells the number of fission and fusion events per frame are very similar,

supporting the concept that these dynamic events are in equilibrium and constantly occurring in

tandem to one another under physiological conditions. By contrast, in patient cells, the reduced

number of fission events was accompanied by a significantly decreased number of fusion events

(Fig. 7A). Thus, defective fission leads to fewer fusion events contributing to decreased dynamic

mitochondrial network phenotype seen in patient cells.

The deleterious effects of fission deficiency have been shown to be restored by the concomitant

deletion of the mitochondrial fusion machinery (Chen H., et al., 2015). To further determine the

contribution of fusion to the mitochondrial network phenotype, we next tested whether deletion of

MFN2 would rescue the mitochondrial hyperfusion phenotype in patient fibroblasts. Indeed, MFN2

deletion restored all the parameters of mitochondrial morphology altered by DRP1 mutations (Fig.

7B), while the peroxisomal elongation was not completely restored (Supplementary Fig. 5).

Collectively these results show that the mitochondrial hyperfusion phenotype can be rescued by

modulating the levels of mitochondrial fusion.

Discussion

DRP1 is an essential gene for embryonic development (Ishihara et al., 2009; Wakabayashi et al.,

2009). RNAi based approaches in human cell culture models have been used to explore the

impact of DRP1 loss on mitochondrial fission and downstream processes such as apoptosis and

mitophagy (Kleele et al., 2021; Otera et al., 2016; Smirnova et al., 2001). Although loss of DRP1

results in mitochondrial hyperfusion, it's not fully understood how mutations in DRP1 can impact

cellular metabolic function, cristae structure, and/or peroxisomal function. The analysis of

organelle morphology in fibroblast lines derived from patients with EMPF1 that harbor one wild-

type copy of DRP1 and one missense copy of DRP1, demonstrate a dominant negative effect of

mutant DRP1 that results in stalling of the fission machinery that has a wide impact on cellular

function.

Mitochondrial fission is essential for cellular processes such as apoptosis, mitophagy, and

mitochondrial biogenesis. However, how mitochondrial fission helps maintain cristae structure

and/or cellular metabolism have not been thoroughly explored. Our studies revealed that while

DRP1 is recruited to the mitochondria in EMPF1 patient cell lines, the fission event is incomplete,

and thus, mitochondrial fission is paused. This stalling of mitochondrial fission results in dramatic

changes to cristae morphology, notably a decrease in cristae score and number, indicative of

immature and poorly formed cristae. Changes in redox signaling can lead to cysteine oxidation of

MIC60 (Li et al., 2021; Wasilewski and Chacinska, 2021), an inner mitochondrial membrane

protein responsible for cristae structure integrity. Thus, the lack of proper mitochondrial fission in

patient cells may disrupt redox signaling, which may in turn be responsible for the aberrant cristae

morphology detected in patient cells.

Detailed metabolic analysis of patient fibroblasts showed that these cells have decreased

coupling efficiency and upregulation of glycolysis, suggesting that the functional impact of stalled

fission is electron transport chain inefficiency. This inefficiency may be due to the changes in

cristae structure, since cristae structure is essential for F_0F_1–ATPase to function effectively (Afzal

et al., 2021; Cogliati et al., 2013; Davies et al., 2011; Wilkens et al., 2013). Previous studies

revealed that there are distinct fission signatures that are key determinants of the decision of

mitochondria to proliferate or degrade (Kleele et al., 2021). Peripheral fission events were shown

to be preceded by a decrease in membrane potential and proton motive force. We found that the

elongated mitochondria from patient fibroblasts have a hyperpolarized membrane potential, which

could result from inefficient function of the F_0F_1–ATPase. Under certain conditions, the F_0F_1–

ATPase can pump protons out of the mitochondrial matrix into the intermembrane space in a

reverse-mode action, causing ΔΨm hyperpolarization. Alternatively, hyperpolarization may be

due to complex I inhibition or VDAC (voltage-dependent anion channel) opening, which can cause

hyperpolarization independently of F_0F_1–ATPase reverse-mode action (Forkink et al., 2014). A

comprehensive analysis of the functionality of the ETC complexes would be needed to elucidate

the connection between fission stalling events and mitochondrial hyperpolarization. Upregulation

of glycolysis in these patient fibroblasts could result in subsequent glucose depletion locally within

the cells, which could in turn cause ΔΨm hyperpolarization. Carbon-tracing could help reveal

whether all of the products of glycolysis are efficiently shuttled into the TCA cycle or if

intermediates are lost in the process. Investigating the function of uncoupling proteins such as

UCP2 and UCP3 may elucidate whether the decreased efficiency is a byproduct or cause of

mitochondrial dysfunction, such as increased ΔΨm, in these cells. Our finding that cells with

DRP1 mutations have profound alterations in cristae morphology but apparent maintenance of

overall ATP production, raises the interesting possibility that DRP1 mutant cells have evolved

specialized mechanisms to cope with electron leakage and damaging reactive oxygen species. A

landmark study from Spinelli and collaborators demonstrated the ability of complex II to work in

reverse in some tissues with the intrinsic capacity to use fumarate as a terminal electron acceptor

(Spinelli et al., 2021). It is plausible that complex II reversal has evolved as a mechanism to

maintain mitochondrial function in cells with alterations in fission caused by DRP1 mutations.

The existence of two mechanistically and functionally distinct types of fission at the mitochondria

and the peroxisomes have not been clearly elucidated. In our study, we demonstrate that patient

fibroblasts with mutations in DRP1 also have elongated peroxisomal morphology. Previous

studies in mammalian cell culture revealed that peroxisome membrane elongation precedes

membrane constriction and final membrane fission (Delille et al., 2010; Schrader et al., 2016).

Whether peroxisomes have a specialized fusion machinery is still under debate. However, we

speculate that under particular metabolic conditions, peroxisomes, particularly those in contact

with mitochondria, may be able to fuse to respond to cellular metabolic needs. Elongation of the

peroxisomes in various human disorders has been associated with alterations in fatty acid

oxidation (Waterham et al., 2016). However, in these cells, peroxisomal function cannot be fully

dissociated from changes in mitochondrial morphology. Our results suggest that MFN2 silencing

could serve as a useful tool to discern the contribution of peroxisomal elongation independently

of the mitochondrial network. Our model (Fig. 7) suggests that the mechanistic and functional

connection between peroxisome remodeling and metabolic homeostasis could be dysregulated

in mitochondrial diseases such EMPF1. We propose that in this context, human diseases could

provide insight into the causal mechanisms underlying basic cellular processes, such as organelle

fission. The detailed elucidation of DRP1-centric mechanisms will reveal the connection between

organelle dynamics and cell fate. Several questions remain: Does stalling of mitochondrial fission

affect the association/dissociation of other proteins at the site of fission? Is peripheral fission also

inhibited in patient fibroblasts? If that is the case, what are the consequences for mitophagy and

mitochondrial DNA integrity? What are the effects of peroxisomal elongation on fatty acid

metabolism? How is cell division and mitochondrial segregation affected by DRP1 mutations?

How are cell fate transitions affected by DRP1 mutations? Answering these fundamental

questions would provide insight into the mechanisms of mitochondrial fission under the lens of

this rare disease caused by dysregulated mitochondrial and peroxisomal homeostasis and inform

the field on more rational and specific therapeutic targets for these devastating

neurodevelopmental disorders.

STAR Methods

Cell Culture

Human fibroblasts were thawed and plated directly in maintenance medium consisting of MEM

(Gibco #11095098) with 10% FBS (Sigma-Aldrich #F2442) and non-essential amino acids (Gibco

11-140-050). Cells were maintained at 37°C and 5% CO2 with media changes every other day.

Cells were passaged as needed using TrypLE (Thermo Fisher #12-064-013). For imaging

experiments, cells were re-plated onto #1.5 glass-bottom 35 mm dishes (Cellvis #D35C4-20-1.5-

N).

Cell Treatments

All treatments were added directly to fibroblasts in maintenance medium. The electron transport

chain decoupler CCCP (Sigma-Aldrich #C2759-250MG) was added to cells at a concentration of

1 µM. Cells were treated for 2 hours prior to fixation and imaging. All stock solutions were prepared

in DMSO.

Plasmid Transfection

Plasmid encoding mCherry-DRP1 (Addgene #49152) was transfected using FuGENE (Promega

#E2311) as described in the manufacturer protocol. Patient mutations were introduced to

plasmids using the In Fusion cloning kit (Takara Bio #638909) as described in the manufacturer

protocol. Cells were maintained until optimal transfection efficiency was reached before cells were

imaged.

siRNA Transfection

siRNA knockdown against MFN2 (Thermo Fisher #s19260) or negative control scrambled was

performed using Lipofectamine RNAiMAX tranfection reagent (Thermo Fisher # 13778150). Cells

were fixed and stained 48hrs after transfection.

Immunofluorescence

For immunofluorescence, cells were fixed with 4% paraformaldehyde for 20 min and

permeabilized in 1% Triton-X-100 for 10 min at room temperature. After blocking in 10% BSA,

cells were treated with primary and secondary antibodies using standard methods. Cells were

mounted in Fluoromount-G (Electron Microscopy Sciences #17984-25) prior to imaging. Primary

antibodies used include mouse anti-Mitochondria (Abcam #ab92824), rabbit anti-Tom20 (Cell

Signaling Technology #42406S), rabbit anti-DRP1 (Cell Signaling Technology #8570S), rabbit

anti-HSP60 (Cell Signaling Technologies # 12165S), mouse anti-PMP70 (Thermo Fisher # MA5-

31368), and rabbit anti-pDRP1 S616 (Cell Signaling Technology #3455S). Secondary antibodies

used include donkey anti-mouse Alexa Fluor-488 (Thermo Fisher Scientific #A21202), donkey

anti-rabbit Alexa Fluor-488 (Thermo Fisher Scientific #A21206), and donkey anti-mouse Alexa

Fluor-546 (Thermo Fisher Scientific #A10036), and donkey anti-rabbit Alexa Fluor-546 (Thermo

Fisher Scientific #A10040).

Western Blot

Gel samples were prepared by mixing cell lysates with LDS sample buffer (Life Technologies,

#NP0007) and 2-Mercaptoethanol (BioRad #1610710) and boiled at 95°C for 5 minutes. Samples

were resolved on 4-20% Mini-PROTEAN TGX precast gels (BioRad #4561096) and transferred

onto PVDF membrane (BioRad #1620177). Antibodies used for Western blotting are as follows:

rabbit anti-DRP-1 (Cell Signaling Technologies #8570S), rabbit anti-pDRP-1 S616 (Cell Signaling

Technologies #3455S), rabbit anti-OPA1 (Cell Signaling Technologies #67589S), mouse anti-

MFN1 (Abcam #ab57602, mouse anti-MFN2 (Abcam #ab56889), rabbit anti-MFF (Proteintech

#17090-1-AP), rabbit anti-MiD49 (Proteintech #16413-1-AP), rabbit anti-MiD51 (Proteintech

#20164-1-AP), and rabbit anti-FIS1 (Proteintech #10956-1-AP), and mouse anti-HSP70

(Invitrogen #MA3-006).

Seahorse XF Analysis

Fibroblasts were plated onto Seahorse XF96 V3 PS cell culture microplates 2 days before the

assay at 50,000 cells per well. One hour prior to the assay, media was switched to XF DMEM

media containing 1 mM pyruvate, 2 mM glutamine, and 10 mM glucose. For the Seahorse XF

Mito Stress Test, oxygen consumption rate (OCR) was measured sequentially after addition of

1.0 µM oligomycin, 0.5 µM FCCP, and 0.5 µM rotenone plus Antimycin A. Protein leak and

coupling efficiency were calculated using OCR. For the Seahorse XF Glycolytic Rate Assay, basal

glycolytic rate was measured by extracellular acidification, and compensatory glycolysis was

measured after addition of 0.5 µM rotenone plus antimycin A. Treatment with 50 mM 2-DG was

used as a negative control. For the Seahorse XF Fuel Flex Test, glutamine dependency was

measured by sequential addition of 3.0 µM BPTES followed by 4.0 µM Etomoxir plus 2.0 µM

UK5099. Fatty acid dependency was measured by sequential addition of 4.0 µM Etomoxir

followed by 3.0 µM BPTES plus 2.0 µM UK5099. Glucose dependency was measured by

sequential addition of 2.0 µM UK5099 followed by 3.0 µM BPTES plus 4.0 µM Etomoxir. For the

Seahorse XF Long Chain Fatty Acid Oxidation Stress Test, 24 hours prior to assay cells were

switched to base media containing 0.5 mM glucose, 1.0 mM glutamine, 0.5 mM XF L-carnitine,

and 1.0 % fetal bovine serum. One hour prior to the assay, media was switched to XF DMEM

media containing 2 mM glucose, 0.5 mM L-Carnitine, and Palmitate-BSA. Oxygen consumption

rate (OCR) was measured sequentially after addition of 4.0 µM etomoxir, 1.5 µM oligomycin, 2.0

µM FCCP, and 0.5 µM rotenone plus Antimycin A.

O2K Analysis

Oxygen consumption was measured with an O2K system (OROBOROS) using Protocols 1 and

2 described in Ye and Hoppel, 2013. Briefly, 2 ml of cell suspension (600,000 cells/ml) in Mir05

buffer was added to each chamber. Initial substrates were added (malate and pyruvate in protocol

1 and malate and palmitoylcarnitine in protocol 2) followed by addition of digitonin in increments

(2ug/ml) to permeabilize the cell membranes. The final concentration of substrates and inhibitors

was composed of malate (2 mM), pyruvate (2.5 mM), adenosine diphosphate (ADP, 2.5 mM),

glutamate (10 mM), succinate (10 mM), palmitoylcarnitine (10 µM), duroquinol (0.5 mM),

etramethyl-p-phenylenediamine (TMPD, 0.5 µM), ascorbate (2 mM), carbonylcyanide-p-

trifluoromethoxy- phenylhydrazone (FCCP, 0.5-µM increment), rotenone (75 nM), antimycin A

(125 nM), and sodium azide (200 mM). For Protocol 1, the non-mitochondrial (AA-insensitive) rate

was subtracted. For Protocol 2, the Rot-insensitive rate was subtracted. For DHQ, the AA was

subtracted.

RNA Extraction and cDNA Synthesis

Cells were washed with PBS and scraped into 1000µl Trizol reagent. 200µl of chloroform was

added and the samples were incubated at room temperature for 5 minutes. The samples were

spun down at 12,000 g and the aqueous phase was collected. 500µl of isopropanol was added

to precipitate RNA and the sample was incubated for 25 minutes at room temperature, followed

by centrifugation at 12,000 g for 10 min at 4°C. The RNA pellet was washed with 75% ethanol,

semi-dried, and resuspended in 30µl of DEPC water. After quantification and adjusting the volume

of all the samples to 1µg/µl, the samples were treated with DNAse (New England Biolabs, #

M0303). 10µl of this volume was used to generate cDNA using the manufacturer's protocol

(Thermo Fisher, #4368814).

Quantitative RT PCR (RT-qPCR)

1ug of cDNA sample was used to run RT-qPCR for the primers mentioned in the table.

QuantStudio 3 Real-Time PCR machine, SYBR green master mix (Thermo Fisher, #4364346),

and manufacturer instructions were used to set up the assay.

Image Acquisition

Super-resolution images were acquired using a Nikon SIM microscope equipped with a 1.49 NA

100x Oil objective an Andor DU-897 EMCCD camera. Live-imaging experiments were acquired

on a Nikon Eclipse Ti-E spinning disk confocal microscope equipped with a 1.40 NA 60X Oil

objective and an Andor DU-897 EMCCD camera. Image processing and quantification was

performed using Fiji.

Sample Preparation for Transmission Electron Microscope (TEM) Analysis

Human fibroblasts were immediately washed in ice-cold saline. Samples were processed as described by (Lam et. al., 2021, Pereira et al., 2017). Cells were fixed in 2.5% glutaraldehyde in sodium cacodylate buffer for 1 hour at 37 °C, embedded in 2% agarose, postfixed in buffered 1% osmium tetroxide, stained in 2% uranyl acetate, and dehydrated with an ethanol graded series. After embedding in EMbed-812 resin, 80 nm sections were cut on an ultramicrotome and stained with 2% uranyl acetate and lead citrate. Images were acquired on a JEOL JEM-1230 Transmission Electron Microscope, operating at 120 kV. Random images of human fibroblasts were obtained.

TEM Analysis

Measurements of mitochondrial area, circularity, and length were performed using the multi-measure region of interest (ROI) tool in ImageJ (Lam et. al., 2021, Parra et al., 2014). To measure cristae morphology, we used ROIs in ImageJ to determine the cristae area, circulatory index, number, volume, and cristae score. The NIH ImageJ software was used to manually trace and analyze all mitochondria or cristae using the freehand told in the ImageJ application (Lam et. al., 2021, Parra et al., 2014). To assign a mitochondrion a cristae score, cristae abundance and form were evaluated. A score between 0 and 4 (0 – no sharply defined crista, 1 – greater than 50% of mitochondrial area without cristae, 2 – greater than 25% of mitochondrial area without cristae, 3 – many cristae but irregular, 4 – many regular cristae) was assigned (Eisner et al., 2017).

Serial Block Facing-Scanning Electron Microscopy (SBF-SEM) Processing

Human fibroblasts were fixed in 2% glutaraldehyde in 0.1 M cacodylate buffer and processed using a heavy metal protocol adapted from a previously published protocol (Courson et al., 2021; Mustafi et al., 2014). Human fibroblasts were immersed in 3% potassium ferrocyanide and 2% osmium tetroxide (1 hour at 4 °C), followed by filtered 0.1% thiocarbohydrazide (20 min), 2% osmium tetroxide (30 min), and left overnight in 1% uranyl acetate at 4 °C (several de-ionized

H2O washes were performed between each step). The next day samples were immersed in a

0.6% lead aspartate solution (30 min at 60 °C and dehydrated in graded acetone (as described

for TEM). Human fibroblasts were impregnated with epoxy Taab 812 hard resin, embedded in

fresh resin, and polymerized at 60 °C for 36–48 hours. After polymerization, the block was

sectioned for TEM to identify the area of interest, then trimmed to 0.5 mm × 0.5 mm and glued to

an aluminum pin. The pin was placed into an FEI/Thermo Scientific Volumescope 2 scanning

electron microscope (SEM). The scope is a state-of-the-art SBF imaging system. For 3D EM

reconstruction, thin (0.09 µm) serial sections, 300 to 400 per block, were obtained from the blocks

that were processed for conventional TEM. Serial sections were collected onto formvar coated

slot grids (Pella, Redding CA), stained, and imaged, as described above. The segmentation of

SBF-SEM reconstructions was performed by manually tracing structural features through

sequential slices of the micrograph block. Images were collected from 30–50 serial sections,

which were then stacked, aligned, and visualized using Amira to make videos and quantify

volumetric structures.

Mitochondrial Event Localizer (MEL)

The MEL algorithm processes a fluorescence microscopy time-lapse sequence of z-stack images

of Mitotracker- labeled mitochondria and produces event counts per frame and 3D locations

indicating where mitochondrial events are likely to have occurred at each time step(Theart et al.,

2020). These locations can subsequently be superimposed on the z-stacks to indicate the

different mitochondrial events. The algorithm has been organized into two consecutive steps,

namely the image pre-processing step which normalizes and prepares the time-lapse frames, and

the automatic image analysis step which calculates the location of the mitochondrial events based

on the normalized frames. MEL also allows each event to be subsequently validated and removed

from the visualization and event counts. The code is available for download:

https://github.com/rensutheart/MEL-Fiji-Plugin.

Statistical Analysis

All experiments were performed with a minimum of 3 biological replicates. Statistical significance was determined by one-way or repeated measures one-way analysis of variance (ANOVA) as appropriate for each experiment. significance was assessed using Fisher's protected least significance difference test. GraphPad PRISM v8.1.2and Statplus software package were used GraphPad Prism was used for all statistical analysis (SAS Institute: Cary, NC, USA). and data visualization. Error bars in all bar graphs represent standard error of the mean unless otherwise noted in the figure. No outliers were removed from the analyses. Quantification of mitochondrial morphology was performed in NIS-Elements (Nikon); briefly, we segmented mitochondria in 3D and performed skeletonization of the resulting 3D mask. Skeleton major axis length, volume, and surface area measurements were exported into Excel. For all statistical analyses, a significant difference was accepted when $P < 0.05$.

Acknowledgements

We would like to thank the patients and families for permission to publish this work. We thank Dr. Eric Payne and Dr. Suzanne Hoppins for providing the patient-derived fibroblast lines used in this paper. We would also like to thank Dr. Evan Krystofiak for providing EM expertise, and Dr. Matthew Tyska, Dr. Uri Manor, and Dr. Kari Seedle, for providing advice and expertise with high-resolution microscopy. This work was supported by 1R35 GM128915-01NIGMS (VG), 1RF1MH123971-01 (VG); the Precision Medicine and Mental Health Initiative sponsored by the Vanderbilt Brain Institute (VG), 1R21CA227483-01A1NCI (VG), F99NS125829 (GLR), HHMI Gilliam (GLR), and CBMS T32 (GLR). All SIM and spinning disk confocal microscopy imaging and image analysis were performed in part through the use of the Vanderbilt Cell Imaging Shared Resource, which is supported by NIH grants 1S10OD012324-01 and 1S10OD021630-01. The authors declare no competing financial interests.

Author Contributions

G. Robertson and V. Gama conceived the study, designed experiments, interpreted data, and wrote the manuscript. V. Gama supervised the research. G. Robertson designed and carried out all the cell biology experiments, with technical assistance from M. Patel and S. Riffle. J. Mears and M. Stoll performed the O2K experiments and provided technical feedback and insight into the conception and execution of study. A. Marshall, H. Beasley, Z. Vue, J. Shao, and E. Garza Lopez performed the TEM, 3D EM and sbf-SEM experiments, quantification, and analysis, with the supervision of A. Hinton. S. de Wet, R. P. Theart, and Ben Loos, applied the MEL algorithm to the mitochondrial imaging data to calculate fission and fusion events. All authors edited the document.

Figure Legends

Figure 1. DRP1 patient-derived fibroblasts have elongated mitochondrial morphology. (A) Structural and schematic representation of DRP1 with mutations highlighted in red. (B) Representative images of mitochondrial morphology in patient-derived fibroblasts using structured illumination microscopy (n=3, 7 cells per replicate). (C) Quantification of mitochondrial volume, surface area, and major axis length. Analyzed using one-way ANOVA followed by Dunnett's multiple comparison test. (D) Representative sbf-SEM 3D reconstructed images. Each mitochondrion is colored a unique color. (E) Quantification of sbf-SEM for 3D mitochondrial length, volume, and complexity index. Analyzed using one-way ANOVA followed by Dunnett's multiple comparison test. (F) Representative images of mitochondrial morphology in control fibroblasts transfected with either DRP1^{WT}-mCherry, DRP1^{G32A}-mCherry, or DRP1^{R403C}-mCherry using structured illumination microscopy (n=3, 7 cells per replicate). (G) Quantification of mitochondrial volume, surface area, and major axis length. Analyzed using one-way ANOVA followed by Dunnett's multiple comparison test.

Figure 2. Mutant G32A and R403C DRP1 are recruited to mitochondria. (A) Western blot of total protein lysate isolated from patient fibroblasts and probed for mitochondrial fusion proteins. Representative image of three independent biological replicates. Band density is normalized to loading control (HSP70) and relative to control cells. (B) Western blot of total protein lysate isolated from patient fibroblasts and probed for mitochondrial fission proteins. Band density is normalized to loading control (HSP70) and relative to control cells. Representative image of three independent biological replicates. (C) Representative images of mitochondrial and DRP1 in patient-derived fibroblasts using structured illumination microscopy (n=3, 7 cells per replicate). Top image is a zoom of white box from bottom image. (D) Quantification of DRP1 puncta that overlap with mitochondria and volume of DRP1 puncta. Analyzed using one-way ANOVA followed by Dunnett's multiple comparison test. (E) Representative images of mitochondrial morphology in patient-derived fibroblasts treated with either DMSO or CCCP for 1 hours using structured illumination microscopy (n=3, 7 cells per replicate). (F) Quantification of mitochondrial volume, surface area, and major axis length. Analyzed using one-way ANOVA followed by Dunnett's multiple comparison test.

Figure 3. Mitochondrial defects lead to inefficient coupling of the electron transport chain and higher glycolytic rate. (A) Oxygen consumption rate and extracellular acidification rate in patient fibroblasts as measured using Seahorse Mitochondrial stress test (n=3, 20 wells per replicate). Oligomycin applied at 20 minutes, FCCP applied at 40 minutes, and rotenone/Antimycin A applied at 60 minutes. Analyzed using two-way ANOVA followed by Šídák's multiple comparisons test. (B) Proton leak and coupling efficiency calculated using oxygen consumption rate. (C) Basal glycolysis of patient fibroblasts measure using Seahorse Glycolytic Rate Assay. Compensatory glycolysis measured following application of rotenone/Antimycin A. (D-L) O_2 consumption rate of intact cells followed by isolated complex O_2 consumption using protocol 1. Analyzed using one-way ANOVA followed by Dunnett's multiple comparison test. (M-

R) O_2 consumption rate of intact cells followed by isolated complex O_2 consumption using protocol

2. Analyzed using one-way ANOVA followed by Dunnett's multiple comparison test.

Figure 4. DRP1 patient fibroblasts have more hyperpolarized mitochondrial membrane

potential. (A) Representative live-cell imaging of patient-derived fibroblasts treated with 500nM

TMRE for 10 minutes. Cells were imaged every 15 seconds for 15 minutes using spinning disk

confocal (n=3, 7 cells per replicate). Scale bar: 5 µm.

Figure 5. Cristae morphology is altered in patient cells. (A) Transmission electron microscopy

of patient fibroblasts. 3 representative images per line shown. (B) Quantification of cristae from

TEM images for cristae score and cristae number relative to mitochondrial length. Analyzed using

one-way ANOVA followed by Dunnett's multiple comparison test.

Figure 6. Patient fibroblasts have elongated peroxisomes. (A) Representative images of

peroxisomal morphology in patient-derived fibroblasts using structured illumination microscopy

(n=3, 7 cells per replicate). (B) Quantification of peroxisomal volume, surface area, and major

axis length. Analyzed using one-way ANOVA followed by Dunnett's multiple comparison test. (C)

qRT-PCR analysis of gene expression in fibroblasts relative to control and normalized to two

housekeeping genes (*GPI* and *GAPDH)*. Quantifications are shown for three independent

biological replicates. (D) Oxygen consumption rate in patient fibroblasts as measured using

Seahorse Analyzer XFe96 (n=3, 20 wells per replicate). Etomoxir applied after 20 minutes,

oligomycin applied at 40 minutes, FCCP applied at 60 minutes, and rotenone/Antimycin A applied

at 80 minutes. Analyzed using two-way ANOVA followed by Šídák's multiple comparisons test.

(E) OCR at maximal respiration after FCCP treatment.

Figure 7: Current model of the cellular responses to EMPF1 associated DRP1 mutations.

(A) Representative images of mitochondrial dynamics in patient-derived fibroblasts treated with

Mitotracker Green with fission events marked in green and fusion events marked in red (7 cells

per replicate). (B) Quantification of mitochondrial dynamics using MEL. Analyzed using one-way

ANOVA followed by Dunnett's multiple comparison test. (C) Representative images of

mitochondrial and peroxisomal morphology in patient-derived fibroblasts treated with either siRNA

against MFN2 or scrambled using structured illumination microscopy (n=3, 7 cells per replicate).

(D) Quantification of mitochondrial volume, surface area, and major axis length. Analyzed using

one-way ANOVA followed by Dunnett's multiple comparison test. (E) Summary schematic:

EMPF1- associated mutations do not appear to alter the capacity of DRP1 to be recruited to points

of fission, but rather cause stalling of the fission events. Pausing peroxisomal and mitochondrial

fission results in alterations of cristae structure, changes in mitochondrial membrane potential,

decreased mitochondrial coupling efficiency, delayed cell death response, and overall metabolic

adaptations.

References

Afzal N, Lederer WJ, Jafri MS, Mannella CA. 2021. Effect of crista morphology on mitochondrial ATP output: A computational study. *Current Research in Physiology* **4**:163–176. doi:10.1016/J.CRPHYS.2021.03.005

Alexander C, Votruba M, Pesch UEA, Thiselton DL, Mayer S, Moore A, Rodriguez M, Kellner U, Leo-Kottler B, Auburger G, Bhattacharya SS, Wissinger B. 2000. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. *Nature Genetics 2000 26:2* **26**:211–215. doi:10.1038/79944

Bayraktar EC, Baudrier L, Özerdem C, Lewis CA, Chan SH, Kunchok T, Abu-Remaileh M, Cangelosi AL, Sabatini DM, Birsoy K, Chen WW. 2019. MITO-Tag Mice enable rapid isolation and multimodal profiling of mitochondria from specific cell types in vivo. *Proc Natl Acad Sci U S A* **116**:303–312. doi:10.1073/pnas.1816656115

Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, Chen YC, Cox JE, Cardon CM, Van Vranken JG, Dephoure N, Redin C, Boudina S, Gygi SP, Brivet M, Thummel CS, Rutter J. 2012. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. *Science* **337**:96–100. doi:10.1126/SCIENCE.1218099

Chakrabarti R, Ji WK, Stan R V., Sanz J de J, Ryan TA, Higgs HN. 2018. INF2-mediated actin polymerization at the ER stimulates mitochondrial calcium uptake, inner membrane constriction, and division. *J Cell Biol* **217**:251–268. doi:10.1083/JCB.201709111

Chandel NS. 2021. Lipid Metabolism. *Cold Spring Harb Perspect Biol* **13**. doi:10.1101/CSHPERSPECT.A040576

Chang C, Blackstone C. 2007. Drp1 phosphorylation and mitochondrial regulation. *EMBO Rep* **8**:1088–1089. doi:10.1038/sj.embor.7401118

Chao YH, Robak LA, Xia F, Koenig MK, Adesina A, Bacino CA, Scaglia F, Bellen HJ, Wangler MF. 2016. Missense variants in the middle domain of DNM1L in cases of infantile encephalopathy alter peroxisomes and mitochondria when assayed in Drosophila. *Human Molecular Genetics* **25**:1846–1856. doi:10.1093/HMG/DDW059

Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. 2003. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *Journal of Cell Biology* **160**:189–200. doi:10.1083/JCB.200211046

Cogliati S, Frezza C, Soriano ME, Varanita T, Quintana-Cabrera R, Corrado M, Cipolat S, Costa V, Casarin A, Gomes LC, Perales-Clemente E, Salviati L, Fernandez-Silva P, Enriquez JA, Scorrano L. 2013. Mitochondrial Cristae Shape Determines Respiratory Chain Supercomplexes Assembly and Respiratory Efficiency. *Cell* **155**:160–171. doi:10.1016/J.CELL.2013.08.032

Csordás G, Renken C, Várnai P, Walter L, Weaver D, Buttle KF, Balla T, Mannella CA, Hajnóczky G. 2006. Structural and functional features and significance of the physical

linkage between ER and mitochondria. *Journal of Cell Biology* **174**:915–921. doi:10.1083/jcb.200604016

Davies KM, Strauss M, Daum B, Kief JH, Osiewacz HD, Rycovska A, Zickermann V, Kühlbrandt W. 2011. Macromolecular organization of ATP synthase and complex I in whole mitochondria. *Proc Natl Acad Sci U S A* **108**:14121–14126. doi:10.1073/PNAS.1103621108/-/DCSUPPLEMENTAL

Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, Pelloquin L, Grosgeorge J, Turc-Carel C, Perret E, Astarie-Dequeker C, Lasquellec L, Arnaud B, Ducommun B, Kaplan J, Hamel CP. 2000. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. *Nature Genetics 2000 26:2* **26**:207–210. doi:10.1038/79936

Delille HK, Agricola B, Guimaraes SC, Borta H, Lüers GH, Fransen M, Schrader M. 2010. Pex11pbeta-mediated growth and division of mammalian peroxisomes follows a maturation pathway. *J Cell Sci* **123**:2750–2762. doi:10.1242/JCS.062109

Ding L, Sun W, Balaz M, He A, Klug M, Wieland S, Caiazzo R, Raverdy V, Pattou F, Lefebvre P, Lodhi IJ, Staels B, Heim M, Wolfrum C. 2021. Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis. *Nat Metab* **3**:1648–1661. doi:10.1038/S42255-021-00489-2

Dorn GW. 2015. Mitochondrial dynamism and heart disease: changing shape and shaping change. *EMBO Molecular Medicine* **7**:865–877. doi:10.15252/emmm.201404575

Eisner V, Cupo RR, Gao E, Csordás G, Slovinsky WS, Paillard M, Cheng L, Ibetti J, Chen SRW, Chuprun JK, Hoek JB, Koch WJ, Hajnóczky G. 2017. Mitochondrial fusion dynamics is robust in the heart and depends on calcium oscillations and contractile activity. *Proc Natl Acad Sci U S A* **114**:E859–E868. doi:10.1073/PNAS.1617288114/-/DCSUPPLEMENTAL

Eramo MJ, Lisnyak V, Formosa LE, Ryan MT. 2020. The "mitochondrial contact site and cristae organising system" (MICOS) in health and human disease. *J Biochem* **167**:243–255. doi:10.1093/JB/MVZ111

Fahrner JA, Liu R, Perry MS, Klein J, Chan DC. 2016. A novel de novo dominant negative mutation in DNM1L impairs mitochondrial fission and presents as childhood epileptic encephalopathy. *Am J Med Genet A* **170**:2002–2011. doi:10.1002/AJMG.A.37721

Faitg J, Lacefield C, Davey T, White K, Laws R, Kosmidis S, Reeve AK, Kandel ER, Vincent AE, Picard M. 2021. 3D neuronal mitochondrial morphology in axons, dendrites, and somata of the aging mouse hippocampus. *Cell Reports* **36**. doi:10.1016/J.CELREP.2021.109509/ATTACHMENT/28BF2465-59D0-4B68-BCDD-D3F180754B5F/MMC1.PDF

Fan J, Li X, Issop L, Culty M, Papadopoulos V. 2016. ACBD2/ECI2-Mediated Peroxisome-Mitochondria Interactions in Leydig Cell Steroid Biosynthesis. *Mol Endocrinol* **30**:763–782. doi:10.1210/ME.2016-1008

Ferreira AR, Marques M, Ramos B, Kagan JC, Ribeiro D. 2021. Emerging roles of peroxisomes in viral infections. *Trends Cell Biol*. doi:10.1016/J.TCB.2021.09.010

Fonseca TB, Sánchez-Guerrero Á, Milosevic I, Raimundo N. 2019. Mitochondrial fission requires DRP1 but not dynamins. *Nature*. doi:10.1038/s41586-019-1296-y

Forkink M, Manjeri GR, Liemburg-Apers DC, Nibbeling E, Blanchard M, Wojtala A, Smeitink JAM, Wieckowski MR, Willems PHGM, Koopman WJH. 2014. Mitochondrial hyperpolarization during chronic complex I inhibition is sustained by low activity of complex II, III, IV and V. *Biochimica et Biophysica Acta (BBA) - Bioenergetics* **1837**:1247–1256. doi:10.1016/J.BBABIO.2014.04.008

Fransen M, Lismont C, Walton P. 2017. The Peroxisome-Mitochondria Connection: How and Why? *Int J Mol Sci* **18**. doi:10.3390/IJMS18061126

Friedman JR, Lackner LL, West M, DiBenedetto JR, Nunnari J, Voeltz GK. 2011. ER tubules mark sites of mitochondrial division. *Science (1979)* **334**:358–362. doi:10.1126/SCIENCE.1207385/SUPPL_FILE/FRIEDMAN.SOM.REV1.PDF

Fröhlich C, Grabiger S, Schwefel D, Faelber K, Rosenbaum E, Mears J, Rocks O, Daumke O. 2013. Structural insights into oligomerization and mitochondrial remodelling of dynamin 1-like protein. *EMBO J* **32**:1280–1292. doi:10.1038/EMBOJ.2013.74

Gandre-Babbe S, Van Der Bliek AM. 2008. The novel tail-anchored membrane protein Mff controls mitochondrial and peroxisomal fission in mammalian cells. *Molecular Biology of the Cell* **19**:2402–2412. doi:10.1091/MBC.E07-12-1287/ASSET/IMAGES/LARGE/ZMK0060885640008.JPEG

Garza-Lopez E, Vue Z, Katti P, Neikirk K, Biete M, Lam J, Beasley HK, Marshall AG, Rodman TA, Christensen TA, Salisbury JL, Vang L, Mungai M, AshShareef S, Murray SA, Shao J, Streeter J, Glancy B, Pereira RO, Dale Abel E, Hinton A, Lopez G. 2021. Protocols for Generating Surfaces and Measuring 3D Organelle Morphology Using Amira. *Cells 2022, Vol 11, Page 65* **11**:65. doi:10.3390/CELLS11010065

Hatch AL, Gurel PS, Higgs HN. 2014. Novel roles for actin in mitochondrial fission. *J Cell Sci* **127**:4549–4560. doi:10.1242/JCS.153791

Hatch AL, Ji WK, Merrill RA, Strack S, Higgs HN. 2016. Actin filaments as dynamic reservoirs for Drp1 recruitment. *Mol Biol Cell* **27**:3109–3121. doi:10.1091/MBC.E16-03-0193

Herzig S, Raemy E, Montessuit S, Veuthey JL, Zamboni N, Westermann B, Kunji ERS, Martinou JC. 2012. Identification and functional expression of the mitochondrial pyruvate carrier. *Science* **337**:93–96. doi:10.1126/SCIENCE.1218530

Hsiao CP, Hoppel C. 2018. Analyzing mitochondrial function in human peripheral blood mononuclear cells. *Anal Biochem* **549**:12–20. doi:10.1016/J.AB.2018.03.003

Ishihara N, Nomura M, Jofuku A, Kato H, Suzuki SO, Masuda K, Otera H, Nakanishi Y, Nonaka I, Goto YI, Taguchi N, Morinaga H, Maeda M, Takayanagi R, Yokota S, Mihara K. 2009. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. *Nature Cell Biology* **11**:958–966. doi:10.1038/ncb1907

Itoyama A, Michiyuki S, Honsho M, Yamamoto T, Moser A, Yoshida Y, Fujiki Y. 2013. Mff functions with Pex11pβ and DLP1 in peroxisomal fission. *Biology Open* **2**:998. doi:10.1242/BIO.20135298

Iwata R, Casimir P, Vanderhaeghen P. 2020. Mitochondrial dynamics in postmitotic cells regulate neurogenesis. *Science (1979)* **369**:858–862. doi:10.1126/science.aba9760

Ji WK, Chakrabarti R, Fan X, Schoenfeld L, Strack S, Higgs HN. 2017. Receptor-mediated Drp1 oligomerization on endoplasmic reticulum. *J Cell Biol* **216**:4123–4139. doi:10.1083/JCB.201610057

Ji WK, Hatch AL, Merrill RA, Strack S, Higgs HN. 2015. Actin filaments target the oligomeric maturation of the dynamin GTPase Drp1 to mitochondrial fission sites. *Elife* **4**. doi:10.7554/eLife.11553

Kamerkar SC, Kraus F, Sharpe AJ, Pucadyil TJ, Ryan MT. 2018. Dynamin-related protein 1 has membrane constricting and severing abilities sufficient for mitochondrial and peroxisomal fission. *Nature Communications* **9**:1–15. doi:10.1038/s41467-018-07543-w

Keller N, Paketci C, Edem P, Thiele H, Yis U, Wirth B, Karakaya M. 2021. De novo DNM1L variant presenting with severe muscular atrophy, dystonia and sensory neuropathy. *Eur J Med Genet* **64**. doi:10.1016/J.EJMG.2020.104134

Khacho M, Clark A, Svoboda DS, Azzi J, MacLaurin JG, Meghaizel C, Sesaki H, Lagace DC, Germain M, Harper ME, Park DS, Slack RS. 2016. Mitochondrial Dynamics Impacts Stem Cell Identity and Fate Decisions by Regulating a Nuclear Transcriptional Program. *Cell Stem Cell* **19**:232–247. doi:10.1016/j.stem.2016.04.015

King WT, Axelrod CL, Zunica ERM, Noland RC, Davuluri G, Fujioka H, Tandler B, Pergola K, Hermann GE, Rogers RC, López-Domènech S, Dantas WS, Stadler K, Hoppel CL, Kirwan JP. 2021. Dynamin-related protein 1 regulates substrate oxidation in skeletal muscle by stabilizing cellular and mitochondrial calcium dynamics. *Journal of Biological Chemistry* **297**:101196. doi:10.1016/J.JBC.2021.101196

Kleele T, Rey T, Winter J, Zaganelli S, Mahecic D, Perreten Lambert H, Ruberto FP, Nemir M, Wai T, Pedrazzini T, Manley S. 2021. Distinct fission signatures predict mitochondrial degradation or biogenesis. *Nature* **593**:435–439. doi:10.1038/S41586-021-03510-6

Koch A, Thiemann M, Grabenbauer M, Yoon Y, McNiven MA, Schrader M. 2003. Dynamin-like protein 1 is involved in peroxisomal fission. *J Biol Chem* **278**:8597–8605. doi:10.1074/JBC.M211761200

Koch J, Brocard C. 2012. PEX11 proteins attract Mff and human Fis1 to coordinate peroxisomal fission. *Journal of Cell Science* **125**:3813–3826. doi:10.1242/JCS.102178/263234/AM/PEX11-PROTEINS-ATTRACT-MFF-AND-HFIS1-TO-COORDINATE

Kondadi AK, Anand R, Hänsch S, Urbach J, Zobel T, Wolf DM, Segawa M, Liesa M, Shirihai OS, Weidtkamp-Peters S, Reichert AS. 2020. Cristae undergo continuous cycles of membrane remodelling in a MICOS-dependent manner. *EMBO Rep* **21**:e49776. doi:10.15252/EMBR.201949776

Krahenbuhl S, Chang M, Brass EP, Hoppel CL. 1991. Decreased activities of ubiquinol:ferricytochrome c oxidoreductase (complex III) and ferrocytochrome c:oxygen oxidoreductase (complex IV) in liver mitochondria from rats with hydroxycobalamin[c-

lactam]-induced methylmalonic aciduria. *Journal of Biological Chemistry* **266**:20998–21003. doi:10.1016/S0021-9258(18)54810-9

Lam J, Katti P, Biete M, Mungai M, Ashshareef S, Neikirk K, Lopez EG, Vue Z, Christensen TA, Beasley HK, Rodman TA, Murray SA, Salisbury JL, Glancy B, Shao J, Pereira RO, Abel ED, Hintonjr. A. 2021. A Universal Approach to Analyzing Transmission Electron Microscopy with ImageJ. *Cells 2021, Vol 10, Page 2177* **10**:2177. doi:10.3390/CELLS10092177

Lee YJ, Jeong SY, Karbowski M, Smith CL, Youle RJ. 2004. Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. *Mol Biol Cell* **15**:5001–5011. doi:10.1091/MBC.E04-04-0294

Lewis SC, Uchiyama LF, Nunnari J. 2016. ER-mitochondria contacts couple mtDNA synthesis with Mitochondrial division in human cells. *Science (1979)* **353**. doi:10.1126/SCIENCE.AAF5549

Li L, Conradson DM, Bharat V, Kim MJ, Hsieh CH, Minhas PS, Papakyrikos AM, Durairaj AS, Ludlam A, Andreasson KI, Partridge L, Cianfrocco MA, Wang X. 2021. A mitochondrial membrane-bridging machinery mediates signal transduction of intramitochondrial oxidation. *Nat Metab* **3**:1242–1258. doi:10.1038/S42255-021-00443-2

Li S, Xu S, Roelofs BA, Boyman L, Jonathan Lederer W, Sesaki H, Karbowski M. 2015. Transient assembly of F-actin on the outer mitochondrial membrane contributes to mitochondrial fission. *Journal of Cell Biology* **208**:109–123. doi:10.1083/jcb.201404050

Liu Xingmiao, Zhang Z, Li D, Lei M, Li Q, Liu Xiaojun, Zhang P. 2021. DNM1L-Related Mitochondrial Fission Defects Presenting as Encephalopathy: A Case Report and Literature Review. *Front Pediatr* **9**. doi:10.3389/FPED.2021.626657

Lodhi IJ, Semenkovich CF. 2014. Peroxisomes: a nexus for lipid metabolism and cellular signaling. *Cell Metab* **19**:380–392. doi:10.1016/J.CMET.2014.01.002

Longo F, Benedetti S, Zambon AA, Sora MGN, Di Resta C, De Ritis D, Quattrini A, Maltecca F, Ferrari M, Previtali SC. 2020. Impaired turnover of hyperfused mitochondria in severe axonal neuropathy due to a novel DRP1 mutation. *Hum Mol Genet* **29**:177–188. doi:10.1093/HMG/DDZ211

Losó n OC, Song Z, Chen H, Chan DC. 2013. Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission. *Mol Biol Cell* **24**:659–667. doi:10.1091/MBC.E12-10-0721

Martinou JC, Youle RJ. 2006. Which came first, the cytochrome c release or the mitochondrial fission? *Cell Death Differ* **13**:1291–1295. doi:10.1038/SJ.CDD.4401985

Montecinos-Franjola F, Bauer BL, Mears JA, Ramachandran R. 2020. GFP fluorescence tagging alters dynamin-related protein 1 oligomerization dynamics and creates disassembly-refractory puncta to mediate mitochondrial fission. *Scientific Reports 2020 10:1* **10**:1–16. doi:10.1038/s41598-020-71655-x

Nagashima S, Tábara LC, Tilokani L, Paupe V, Anand H, Pogson JH, Zunino R, McBride
HM, Prudent J. 2020. Golgi-derived PI(4)P-containing vesicles drive late steps of
mitochondrial division. *Science (1979)* **367**:1366–1371. doi:10.1126/science.aax6089

Nasca A, Legati A, Baruffini E, Nolli C, Moroni I, Ardissone A, Goffrini P, Ghezzi D. 2016.
Biallelic Mutations in DNM1L are Associated with a Slowly Progressive Infantile
Encephalopathy. *Human Mutation* **37**:898–903. doi:10.1002/HUMU.23033

Nolan DA, Chen B, Michon AM, Salatka E, Arndt D. 2019. A Rasmussen encephalitis,
autoimmune encephalitis, and mitochondrial disease mimicker: expanding the *DNM1L*-
associated intractable epilepsy and encephalopathy phenotype. *Epileptic Disorders*
21:112–116. doi:10.1684/EPD.2019.1036

Osellame LD, Singh AP, Stroud DA, Palmer CS, Stojanovski D, Ramachandran R, Ryan MT.
2016. Cooperative and independent roles of the Drp1 adaptors Mff, MiD49 and MiD51
in mitochondrial fission. *Journal of Cell Science* **129**:2170–2181.
doi:10.1242/JCS.185165/-/DC1

Otera H, Miyata N, Kuge O, Mihara K. 2016. Drp1-dependent mitochondrial fission via
MiD49/51 is essential for apoptotic cristae remodeling. *Journal of Cell Biology* **212**:531–
544. doi:10.1083/jcb.201508099

Palmer CS, Elgass KD, Parton RG, Osellame LD, Stojanovski D, Ryan MT. 2013. Adaptor
proteins MiD49 and MiD51 can act independently of Mff and Fis1 in Drp1 recruitment
and are specific for mitochondrial fission. *J Biol Chem* **288**:27584–27593.
doi:10.1074/JBC.M113.479873

Prigione A, Adjaye J. 2011. Modulation of mitochondrial biogenesis and bioenergetic
metabolism upon in vitro and in vivo differentiation of human ES and iPS cells.
International Journal of Developmental Biology. doi:10.1387/ijdb.103198ap

Rasmussen ML, Taneja N, Neininger AC, Wang L, Robertson GL, Riffle SN, Shi L,
Knollmann BC, Burnette DT, Gama V. 2020. MCL-1 Inhibition by Selective BH3
Mimetics Disrupts Mitochondrial Dynamics Causing Loss of Viability and Functionality
of Human Cardiomyocytes. *iScience* **23**. doi:10.1016/j.isci.2020.101015

Ravi A, Palamiuc L, Loughran RM, Triscott J, Arora GK, Kumar A, Tieu V, Pauli C, Reist M,
Lew RJ, Houlihan SL, Fellmann C, Metallo C, Rubin MA, Emerling BM. 2021. PI5P4Ks
drive metabolic homeostasis through peroxisome-mitochondria interplay. *Dev Cell*
56:1661-1676.e10. doi:10.1016/J.DEVCEL.2021.04.019

Ryan CS, Fine AL, Cohen AL, Schiltz BM, Renaud DL, Wirrell EC, Patterson MC, Boczek
NJ, Liu R, Babovic-Vuksanovic D, Chan DC, Payne ET. 2018. De Novo DNM1L Variant
in a Teenager With Progressive Paroxysmal Dystonia and Lethal Super-refractory
Myoclonic Status Epilepticus. *Journal of Child Neurology* **33**:651–658.
doi:10.1177/0883073818778203

Schrader M, Costello JL, Godinho LF, Azadi AS, Islinger M. 2016. Proliferation and fission
of peroxisomes - An update. *Biochim Biophys Acta* **1863**:971–983.
doi:10.1016/J.BBAMCR.2015.09.024

Schrader M, Kamoshita M, Islinger M. 2020. Organelle interplay-peroxisome interactions in
health and disease. *J Inherit Metab Dis* **43**:71–89. doi:10.1002/JIMD.12083

Sheffer R, Douiev L, Edvardson S, Shaag A, Tamimi K, Soiferman D, Meiner V, Saada A.
2016. Postnatal microcephaly and pain insensitivity due to a de novo heterozygous
DNM1L mutation causing impaired mitochondrial fission and function. *American Journal*
of Medical Genetics, Part A **170**:1603–1607. doi:10.1002/AJMG.A.37624

Smaili SS, Hsu YT, Sanders KM, Russell JT, Youle RJ. 2001. Bax translocation to
mitochondria subsequent to a rapid loss of mitochondrial membrane potential. *Cell*
Death Differ **8**:909–920. doi:10.1038/SJ.CDD.4400889

Smirnova E, Griparic L, Shurland DL, van der Bliek AM. 2001. Dynamin-related protein Drp1
is required for mitochondrial division in mammalian cells. *Mol Biol Cell* **12**:2245–56.
doi:10.1091/mbc.12.8.2245

Spinelli JB, Rosen PC, Sprenger H-G, Puszynska AM, Mann JL, Roessler JM, Cangelosi
AL, Henne A, Condon KJ, Zhang T, Kunchok T, Lewis CA, Chandel NS, Sabatini DM.
2021. Fumarate is a terminal electron acceptor in the mammalian electron transport
chain. *Science* **374**:1227–1237. doi:10.1126/SCIENCE.ABI7495

Sugiura A, Mattie S, Prudent J, Mcbride HM. 2017. Newly born peroxisomes are a hybrid of
mitochondrial   and   ER-derived   pre-peroxisomes.   *Nature*   **542**:251–254.
doi:10.1038/NATURE21375

Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K. 2007. Mitotic phosphorylation of dynamin-
related GTPase Drp1 participates in mitochondrial fission. *Journal of Biological*
Chemistry **282**:11521–11529. doi:10.1074/jbc.M607279200

Tanaka H, Okazaki T, Aoyama S, Yokota M, Koike M, Okada Y, Fujiki Y, Gotoh Y. 2019.
Peroxisomes   control   mitochondrial   dynamics   and   the   mitochondrion-dependent
apoptosis pathway. *J Cell Sci* **132**. doi:10.1242/JCS.224766

Theart RP, Kriel J, Toit A du, Loos B, Niesler TR. 2020. Mitochondrial event localiser (MEL)
to quantitativelydescribe fission, fusion and depolarisation in the three-dimensional
space. *PLOS ONE* **15**:e0229634. doi:10.1371/JOURNAL.PONE.0229634

Valera-Alberni M, Joffraud M, Miro-Blanch J, Capellades J, Junza A, Dayon L, Núñez
Galindo A, Sanchez-Garcia JL, Valsesia A, Cercillieux A, Söllner F, Ladurner AG,
Yanes O, Cantó C. 2021. Crosstalk between Drp1 phosphorylation sites during
mitochondrial remodeling and their impact on metabolic adaptation. *Cell Reports* **36**.
doi:10.1016/J.CELREP.2021.109565/ATTACHMENT/3EF18C2E-C1FE-434A-A87F-
E1E1BD407021/MMC1.PDF

Vandeleur D, Chen C V., Huang EJ, Connolly AJ, Sanchez H, Moon-Grady AJ. 2019. Novel
and lethal case of cardiac involvement in DNM1L mitochondrial encephalopathy.
American   Journal   of   Medical   Genetics,   Part   A   **179**:2486–2489.
doi:10.1002/AJMG.A.61371

Vantaggiato C, Castelli M, Giovarelli M, Orso G, Bassi MT, Clementi E, De Palma C. 2019.
The Fine Tuning of Drp1-Dependent Mitochondrial Remodeling and Autophagy

Controls Neuronal Differentiation. *Frontiers in Cellular Neuroscience* **13**:120.
doi:10.3389/fncel.2019.00120

Vincent AE, White K, Davey T, Philips J, Ogden RT, Lawess C, Warren C, Hall MG, Ng YS,
Falkous G, Holden T, Deehan D, Taylor RW, Turnbull DM, Picard M. 2019. Quantitative
3D Mapping of the Human Skeletal Muscle Mitochondrial Network. *Cell Reports* **26**:996-
1009.e4. doi:10.1016/J.CELREP.2019.01.010/ATTACHMENT/FB7711C2-65A0-4155-
8EB8-6FD4440E627D/MMC1.PDF

Wai T, Langer T. 2016. Mitochondrial Dynamics and Metabolic Regulation. *Trends in
Endocrinology and Metabolism*. doi:10.1016/j.tem.2015.12.001

Wakabayashi J, Zhang Z, Wakabayashi N, Tamura Y, Fukaya M, Kensler TW, Iijima M,
Sesaki H. 2009. The dynamin-related GTPase Drp1 is required for embryonic and brain
development in mice. *Journal of Cell Biology* **186**:805–816. doi:10.1083/jcb.200903065

Wasiak S, Zunino R, McBride HM. 2007. Bax/Bak promote sumoylation of DRP1 and its
stable association with mitochondria during apoptotic cell death. *J Cell Biol* **177**:439–
450. doi:10.1083/JCB.200610042

Wasilewski M, Chacinska A. 2021. MIC60 relays oxidation to block mitophagy. *Nature
Metabolism 2021 3:9* **3**:1146–1147. doi:10.1038/s42255-021-00460-1

Waterham HR, Ferdinandusse S, Wanders RJA. 2016. Human disorders of peroxisome
metabolism and biogenesis. *Biochimica et Biophysica Acta (BBA) - Molecular Cell
Research* **1863**:922–933. doi:10.1016/J.BBAMCR.2015.11.015

Waterham HR, Koster J, van Roermund CWT, Mooyer PAW, Wanders RJA, Leonard J V.
2007. A lethal defect of mitochondrial and peroxisomal fission. *N Engl J Med* **356**:1736–
1741. doi:10.1056/NEJMOA064436

Whitley BN, Lam C, Cui H, Haude K, Bai R, Escobar L, Hamilton A, Brady L, Tarnopolsky
MA, Dengle L, Picker J, Lincoln S, Lackner LL, Glass IA, Hoppins S. 2018. Aberrant
Drp1-mediated mitochondrial division presents in humans with variable outcomes.
Human Molecular Genetics **27**:3710–3719. doi:10.1093/hmg/ddy287

Wilkens V, Kohl W, Busch K. 2013. Restricted diffusion of OXPHOS complexes in dynamic
mitochondria delays their exchange between cristae and engenders a transitory mosaic
distribution. *J Cell Sci* **126**:103–116. doi:10.1242/JCS.108852

Ye F, Hoppel CL. 2013. Measuring oxidative phosphorylation in human skin fibroblasts. *Anal
Biochem* **437**:52–58. doi:10.1016/J.AB.2013.02.010

Yoon G, Malam Z, Paton T, Marshall CR, Hyatt E, Ivakine Z, Scherer SW, Lee KS, Hawkins
C, Cohn RD. 2016. Lethal Disorder of Mitochondrial Fission Caused by Mutations in
DNM1L. *The Journal of Pediatrics* **171**:313-316.e2. doi:10.1016/J.JPEDS.2015.12.060

1032

DAPI Mitochondria DRP1

DAPI Mitochondria DRP1

A

A

Control — Fusion / Fission

G32A — Fusion / Fission

R403C — Fusion / Fission

B

Control ●   G32A ■   R403C ▲

0.0014

<0.0001

<0.0001

<0.0001

Fission/Fusion events per frame

Fission   Fusion   Fission   Fusion   Fission   Fusion

C

Control   G32A   R403C

siSCR

siMFN2

DAPI   HSP60   PMP70

D

Control ●   G32A ■   R403C ▲

Mitochondrial Volume (µm³)

<0.0001   0.0008

siSCR siMFN2   siSCR siMFN2   siSCR siMFN2

Mitochondrial Surface Area (µm²)

0.0958   <0.0001   0.0004

siSCR siMFN2   siSCR siMFN2   siSCR siMFN2

Major Axis Length (µm)

0.0014   <0.0001   <0.0001

siSCR siMFN2   siSCR siMFN2   siSCR siMFN2

E

Hyperfused peroxisome

Hyperfused mitochondria

EMPF1-associated DRP1 mutations

Stalled fission events

Hyperpolarized mitochondrial membrane potential   Altered cristae structure   Decreased coupling efficiency   Delayed apoptotic response